1. Home
  2. CRBU vs PRQR Comparison

CRBU vs PRQR Comparison

Compare CRBU & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.75

Market Cap

203.9M

Sector

Health Care

ML Signal

HOLD

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

HOLD

Current Price

$1.52

Market Cap

163.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBU
PRQR
Founded
2011
2012
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.9M
163.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
CRBU
PRQR
Price
$1.75
$1.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$10.00
$7.67
AVG Volume (30 Days)
1.4M
325.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.37
$18.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.08
52 Week High
$3.53
$3.10

Technical Indicators

Market Signals
Indicator
CRBU
PRQR
Relative Strength Index (RSI) 50.32 43.96
Support Level $1.71 $1.33
Resistance Level $2.11 $1.58
Average True Range (ATR) 0.15 0.09
MACD 0.01 0.03
Stochastic Oscillator 36.00 51.43

Price Performance

Historical Comparison
CRBU
PRQR

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Share on Social Networks: